eligibility_summary
Adults ≥18 with relapsed/refractory or chemo‑ineligible PEL, PBL, or KSHV‑MCD. HIV allowed if on effective ART and VL<200. PEL/PBL: measurable, ECOG 0–2 (or 3 disease‑related), Hgb>7, CrCl≥15, prior anthracycline unless contraindicated. MCD: ECOG 0–2 (or 3), Hgb>7, CrCl≥15, plus ≥1 symptom and ≥1 MCD‑related lab. HBV suppressed, HCV SVR, washout, contraception. Exclude: recent anticancer tx, urgent KS chemo, high LFTs (exceptions), ANC<1000/Plt<75k (unless disease‑related), cardiac/arrhythmia, severe COPD/asthma, pregnancy, severe uncontrolled illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, single-arm trial testing subcutaneous daratumumab (daratumumab + hyaluronidase), a human monoclonal antibody targeting CD38, in relapsed/refractory primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and KSHV-associated multicentric Castleman disease (MCD). Mechanism: daratumumab binds CD38 and kills CD38+ cells via antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and apoptosis, it also depletes CD38+ immunosuppressive cells, enhancing T-helper and cytotoxic T-cell responses and TCR clonality. Targets: CD38-expressing plasmablast/plasma cell–like tumor cells in PEL/PBL and KSHV-infected CD38+ plasmablasts in MCD, indirect modulation of the IL-6/vIL-6 inflammatory milieu via tumor/suppressor-cell depletion. Dosing: 1800 mg SC weekly → q2w → q4w (modified for MCD).